IL114027A - 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them - Google Patents

4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them

Info

Publication number
IL114027A
IL114027A IL11402795A IL11402795A IL114027A IL 114027 A IL114027 A IL 114027A IL 11402795 A IL11402795 A IL 11402795A IL 11402795 A IL11402795 A IL 11402795A IL 114027 A IL114027 A IL 114027A
Authority
IL
Israel
Prior art keywords
ht1a
alkyl
serotinin
dopamin
tetrahydropyridine
Prior art date
Application number
IL11402795A
Other languages
English (en)
Other versions
IL114027A0 (en
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL114027A0 publication Critical patent/IL114027A0/xx
Publication of IL114027A publication Critical patent/IL114027A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL11402795A 1994-06-08 1995-06-07 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them IL114027A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK65794 1994-06-08

Publications (2)

Publication Number Publication Date
IL114027A0 IL114027A0 (en) 1995-10-31
IL114027A true IL114027A (en) 1999-11-30

Family

ID=8096051

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11402795A IL114027A (en) 1994-06-08 1995-06-07 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them

Country Status (27)

Country Link
US (2) US6514993B1 (sv)
EP (1) EP0770066B1 (sv)
JP (1) JPH10500959A (sv)
KR (1) KR100382812B1 (sv)
CN (1) CN1067057C (sv)
AT (1) ATE193016T1 (sv)
AU (1) AU686400B2 (sv)
BR (1) BR9507930A (sv)
CA (1) CA2192113A1 (sv)
CZ (1) CZ287801B6 (sv)
DE (1) DE69517027T2 (sv)
DK (1) DK0770066T3 (sv)
ES (1) ES2148527T3 (sv)
FI (1) FI964897A (sv)
GR (1) GR3034105T3 (sv)
HK (1) HK1000877A1 (sv)
HU (1) HUT76470A (sv)
IL (1) IL114027A (sv)
MX (1) MX9605863A (sv)
NO (1) NO308534B1 (sv)
NZ (1) NZ288180A (sv)
PL (1) PL180847B1 (sv)
PT (1) PT770066E (sv)
RU (1) RU2140920C1 (sv)
SK (1) SK281646B6 (sv)
WO (1) WO1995033729A1 (sv)
ZA (1) ZA954688B (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
CA2334254A1 (en) * 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
FR2803298A1 (fr) * 1999-12-30 2001-07-06 Adir Nouvelles urees lineaires ou cycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
AU2002221744A1 (en) * 2000-11-14 2002-05-27 Merck Patent Gmbh Novel uses of combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists
ES2280602T3 (es) 2001-07-26 2007-09-16 Merck Patent Gmbh Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
WO2003074518A1 (en) * 2002-03-06 2003-09-12 Merck Patent Gmbh Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20040253576A1 (en) * 2003-04-04 2004-12-16 The Regents Of The University Of California Modulating cooperative activity of dopamine D1 and D2 receptors to mitigate substance abuse
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
EP1817032A2 (en) * 2004-11-29 2007-08-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US8422893B2 (en) 2010-01-21 2013-04-16 Samsung Electronics Co., Ltd Developer and image forming apparatus including the same
WO2013152105A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374237A (en) * 1965-05-21 1968-03-19 American Cyanamid Co 1-phenyl-3-(4-phenyl-1-piperazinoalkyl)-imidazolidinones and imidazolidinethiones
DE2263211A1 (de) * 1972-12-23 1974-07-04 Boehringer Sohn Ingelheim Neue arylpiperazine und verfahren zu ihrer herstellung
US4452798A (en) * 1982-06-22 1984-06-05 Warner-Lambert Company 1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
JPH05507933A (ja) * 1990-06-29 1993-11-11 ジ・アップジョン・カンパニー Ｃｎｓおよび抗高血圧活性を有する置換１―（アルコキシフェニル）ピペラジン類
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5314885A (en) * 1992-09-11 1994-05-24 Mcneilab, Inc. Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents
JPH09504272A (ja) * 1993-09-15 1997-04-28 メルク シヤープ エンド ドーム リミテツド ドーパミンアンタゴニストとしてのイミダゾロン及びオキサゾロン誘導体
US6150367A (en) * 1997-10-20 2000-11-21 Council Of Scientific & Industrial Research 1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propanes and their use in medical treatments

Also Published As

Publication number Publication date
CN1067057C (zh) 2001-06-13
NZ288180A (en) 1998-07-28
NO965183L (no) 1996-12-04
WO1995033729A1 (en) 1995-12-14
US20030120070A1 (en) 2003-06-26
AU2732295A (en) 1996-01-04
US6514993B1 (en) 2003-02-04
AU686400B2 (en) 1998-02-05
NO965183D0 (no) 1996-12-04
PL180847B1 (pl) 2001-04-30
HU9603372D0 (en) 1997-01-28
ATE193016T1 (de) 2000-06-15
DE69517027T2 (de) 2000-12-21
FI964897A0 (sv) 1996-12-05
CA2192113A1 (en) 1995-12-14
FI964897A (sv) 1996-12-05
PT770066E (pt) 2000-11-30
HUT76470A (en) 1997-09-29
NO308534B1 (no) 2000-09-25
BR9507930A (pt) 1997-11-18
ZA954688B (en) 1996-01-29
DE69517027D1 (de) 2000-06-21
GR3034105T3 (en) 2000-11-30
CZ287801B6 (en) 2001-02-14
PL317530A1 (en) 1997-04-14
MX9605863A (es) 1998-06-30
SK154996A3 (en) 1997-08-06
DK0770066T3 (da) 2000-10-09
CN1154107A (zh) 1997-07-09
EP0770066A1 (en) 1997-05-02
RU2140920C1 (ru) 1999-11-10
ES2148527T3 (es) 2000-10-16
KR100382812B1 (ko) 2003-08-21
SK281646B6 (sk) 2001-06-11
HK1000877A1 (en) 2001-11-02
JPH10500959A (ja) 1998-01-27
EP0770066B1 (en) 2000-05-17
CZ358996A3 (en) 1997-05-14
IL114027A0 (en) 1995-10-31

Similar Documents

Publication Publication Date Title
IL114027A (en) 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
AR002986A1 (es) Nuevos derivados de piperazina sustituida particularmente utiles como antagonistas de receptores de taquiquinina, composiciones farmaceuticas, usosde dichos derivados y procedimiento de preparacion de los mismos.
CZ177296A3 (en) Compounds antagonizing tachykinin receptors for morpholine and thiomorpholine, process of their preparation and pharmaceutical compositions containing thereof
HU907660D0 (en) Process for producing tricyclic compounds and pharmaceutical preparatives containing such compounds as active substances
MX9705590A (es) Compuestos heterociclicos sustituidos, procedimiento para su preparacion y composiciones que los contienen.
MX9605864A (es) 4-aril-1-(indanmetil, dihidrobenzofuranmetil o dihidrobenzotiofenmetil)piperidinas, tetrahidroopiridinas o piperazinas.
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
DE69712325D1 (de) Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker
TW334428B (en) Novel benzodiazepine derivatives
MY103831A (en) Lactam derivatives.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees